share_log

While Individual Investors Own 38% of Livzon Pharmaceutical Group Inc. (SZSE:000513), Public Companies Are Its Largest Shareholders With 44% Ownership

While Individual Investors Own 38% of Livzon Pharmaceutical Group Inc. (SZSE:000513), Public Companies Are Its Largest Shareholders With 44% Ownership

雖然個人投資者擁有藥品零售龍頭盈科醫藥集團38%的股權(深交所:000513),但上市公司是其最大的股東,擁有44%的股權。
Simply Wall St ·  08/19 03:17

Key Insights

主要見解

  • Significant control over Livzon Pharmaceutical Group by public companies implies that the general public has more power to influence management and governance-related decisions
  • The top 8 shareholders own 50% of the company
  • Institutions own 15% of Livzon Pharmaceutical Group
  • 公共公司對荔枝成藥集團的重要控制力意味着普通公衆在管理和治理相關決策上擁有更多的影響力。
  • 前8大股東擁有公司50%的股份。
  • 機構持有荔枝成藥集團的15%。

To get a sense of who is truly in control of Livzon Pharmaceutical Group Inc. (SZSE:000513), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company, around 44% to be precise, is public companies. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

爲了了解荔枝成藥集團(SZSE:000513)真正的控制者,了解企業的股權結構很重要。同時,擁有公司最多股份的集團——準確來說是約44%——是公共公司。換句話說,該集團最可能從其投資中獲益(或損失最大)。

Individual investors, on the other hand, account for 38% of the company's stockholders.

另一方面,個人投資者佔公司股東的38%。

In the chart below, we zoom in on the different ownership groups of Livzon Pharmaceutical Group.

在下面的圖表中,我們將聚焦荔枝成藥集團的不同所有權群體。

big
SZSE:000513 Ownership Breakdown August 19th 2024
SZSE:000513所有權結構細分 2024年8月19日

What Does The Institutional Ownership Tell Us About Livzon Pharmaceutical Group?

機構投資者持有荔枝成藥集團的股份,這表明爲這些機構工作的分析師們看好這隻股票,但像其他人一樣,他們也可能是錯誤的。如果兩個大型機構投資者同時嘗試出售一隻股票,股價大幅下跌也不是不可能的。因此,值得檢查荔枝成藥集團過去的盈利軌跡。當然,還要記住需要考慮其他因素。

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

許多機構衡量其業績的標準是一個近似於當地市場的指數。因此,他們通常更加關注包括在主要指數中的公司。

As you can see, institutional investors have a fair amount of stake in Livzon Pharmaceutical Group. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Livzon Pharmaceutical Group, (below). Of course, keep in mind that there are other factors to consider, too.

正如您所看到的,機構投資者擁有荔枝成藥集團的相當比例。這意味着爲這些機構工作的分析師們看好這隻股票。但像其他人一樣,他們也可能是錯誤的。如果兩個大型機構投資者同時嘗試拋出股票,股價大幅下跌也不是不可能的。因此,值得檢查荔枝成藥集團過去的盈利軌跡(如下所示)。當然,還要記住需要考慮其他因素。

big
SZSE:000513 Earnings and Revenue Growth August 19th 2024
SZSE:000513盈利和營業收入增長 2024年8月19日

We note that hedge funds don't have a meaningful investment in Livzon Pharmaceutical Group. Joincare Pharmaceutical Group Industry Co.,Ltd. is currently the company's largest shareholder with 44% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 1.9% and 1.3%, of the shares outstanding, respectively.

我們注意到,對荔枝成藥集團的對沖基金不具備實質性的投資。目前,健康元是該公司的最大股東,持有公司股份的44%。而第二大股東和第三大股東持有的公司股份分別爲1.9%和1.3%。

We did some more digging and found that 8 of the top shareholders account for roughly 50% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

我們對Brookfield Infrastructure有了更深入的了解,發現前8位股東佔持股比例的約50%,這意味着除了大股東外還有少數小股東,從而在一定程度上平衡了彼此的利益。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

雖然仔細研究公司的機構持股數據是有意義的,但研究分析師對該股票的看法也是有意義的。有相當數量的分析師在跟蹤該股票,因此了解他們對於未來發展的總體看法可能會有所幫助。

Insider Ownership Of Livzon Pharmaceutical Group

荔枝成藥集團的內部控制情況

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

公司內部人員的定義可能是主觀的,並且在不同的司法管轄區之間有所不同。我們的數據反映了個人內部人員,至少捕捉到董事會成員的記錄。公司管理人員向董事會報告,後者應該代表股東的利益。值得注意的是,有時高級管理人員自己也在董事會中。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常認爲內部人士持股是一件好事。但是,在某些情況下,它會使其他股東更難以對董事會的決定進行問責。

Our data suggests that insiders own under 1% of Livzon Pharmaceutical Group Inc. in their own names. But they may have an indirect interest through a corporate structure that we haven't picked up on. It's a big company, so even a small proportional interest can create alignment between the board and shareholders. In this case insiders own CN¥116m worth of shares. It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling.

我們的數據表明,內部人士以自己的名義持有的荔枝成藥集團股份不到1%。但是他們可能通過我們沒有發現的公司結構具有間接利益。由於這是一家大公司,所以即使是小比例的持股也可以在董事會和股東之間建立聯繫。在這種情況下,內部人士擁有1,160萬元的股份。看到至少有一些內部人士持股總是件好事,但是還值得檢查這些內部人士是否一直在減持。

General Public Ownership

一般大衆所有權

The general public-- including retail investors -- own 38% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

公衆--包括零售投資者--持有公司的38%股份,因此不容易被忽視。儘管這種規模的持股較大,但如果決策與其他大股東不協調,可能無法改變公司政策。

Public Company Ownership

上市公司所有權

It appears to us that public companies own 44% of Livzon Pharmaceutical Group. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership.

對我們來說,公共公司持有荔枝成藥集團的44%。確定這一點顯然很難,但這表明它們存在着交織的商業利益。這可能是一種戰略性的持股,因此值得關注所有權變化。

Next Steps:

下一步:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Livzon Pharmaceutical Group you should know about.

我認爲着眼於公司的所有者非常有趣。但是要真正獲得洞察力,我們需要考慮其他信息。例如,風險。每家公司都有風險,我們已經發現了荔枝成藥集團的1個警告信號,您應該知道。

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

但最終,決定該業務所有者將獲得多大利益的是未來而非過去。因此,我們認爲最好查看此免費報告,以了解分析師是否預測更光明的未來。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論